Genelex

Genelex is hoping that a recently published randomized-controlled trial will help it get on better footing with Medicare.

The deal could bolster Genelex's business, but CEO Kristine Ashcraft is hopeful that the integration with Epic Systems a sign of growing acceptance of pharmacogenetic testing.

The company's recent experience demonstrates the impasse between genetic test developers and payors about the types of clinical evidence needed for coverage.

Palmetto has informed test developers via its MolDx program that they must register and bill panel tests that gauge multiple molecular markers using a single CPT code and a unique identifier.

European Commission Approves Vertex's Personalized CF Drug Kalydeco

Janet Thornton, the director of the European Bioinformatics Institute, has been made a Dame Commander of the Order of the British Empire in recognition of her contribution to bioinformatics.

By Turna Ray
Two recently published pharmacogenetic analyses looking at the impact of CYP2D6 alleles on tamoxifen response found no evidence that patients who harbor these mutations fail to respond to the hormone therapy.

Genelex can now offer its DNA Drug Sensitivity Tests covering three enzymes involved in drug metabolism.

The firms' merger combines technologies for pharmacogenomic testing and gene-interaction informatics.

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.